EMA Authorised: Skilarence (dimethyl fumarate) — Almirall, S.A.

View source ↗

Summary

EMA has authorized Skilarence (dimethyl fumarate) for the treatment of psoriasis, with Almirall, S.A. as the marketing authorization holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Skilarence (dimethyl fumarate)

Snippet

Status: Authorised. Therapeutic area: Psoriasis. MAH: Almirall, S.A.. Decision date: 17/03/2025